Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Other Accumulated Expenses: 2016-2025

Historic Other Accumulated Expenses for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $2.7 million.

  • Rocket Pharmaceuticals' Other Accumulated Expenses fell 3.50% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 3.50%. This contributed to the annual value of $1.6 million for FY2024, which is 8.30% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Other Accumulated Expenses of $2.7 million as of Q3 2025, which was up 56.41% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Other Accumulated Expenses peaked at $3.1 million during Q2 2024, and registered a low of $482,000 during Q4 2021.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $1.9 million (2023), whereas its average is $2.2 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 371.58% in 2022, then slumped by 44.17% in 2025.
  • Rocket Pharmaceuticals' Other Accumulated Expenses (Quarterly) stood at $482,000 in 2021, then surged by 371.58% to $2.3 million in 2022, then decreased by 22.04% to $1.8 million in 2023, then declined by 8.30% to $1.6 million in 2024, then fell by 3.50% to $2.7 million in 2025.
  • Its Other Accumulated Expenses was $2.7 million in Q3 2025, compared to $1.7 million in Q2 2025 and $2.9 million in Q1 2025.